IngredientsCymbidium goeringii (Rchb.f.) Rchb.f. is a terrestrial orchid belonging to the family Orchidaceae. It belongs to the Orchidaceae, which is one of the most abundant angiosperm families. Within that family, the genus Cymbidium belongs to the Orchidaceae family and is economically important due to their beautiful and fragrant flowers. The species was first formally described by Heinrich Gustav Reichenbach; its basionym is Maxillaria goeringii Rchb.f., published in the Botanische Zeitung (Berlin) in 1845. Several synonyms have been recognised over the years, including Cymbidium pseudovirens Schltr., Cymbidium tentyozanense Masam., Cymbidium uniflorum T.C.Yen, Cymbidium virens Rchb.f., Cymbidium virescens Lindl., and Cymbidium yunnanense Schltr.
The species is formally recognised by the Royal Botanic Gardens, Kew in its Plants of the World Online database (Kew Science Plants of the World Online, maintained by the Board of Trustees of the Royal Botanic Gardens, Kew), and is included in the Flora of China, volume 25 (Wu and Hong, eds., 2009), published by Missouri Botanical Garden Press.
Cymbidium goeringii is also known as the "Spring Orchid," and has a rich history in traditional East Asian medicine, particularly within Chinese and Korean herbal practices. In Chinese, it is commonly called Chun Lan (春兰), meaning "spring orchid." Chinese cymbidiums are commonly known as "Lan" (兰) or "Guo Lan" (国兰) in China, referring to a group of terrestrial cymbidiums belonging to the subgenus Jensoa of genus Cymbidium. The best-known Chinese cymbidiums include C. goeringii (春兰). It is sometimes referred to as the "Noble Orchid" in the contemporary supplement industry. It is a special plant in East Asia and is often deemed the 'scholars' orchid because of the history with China's famous philosopher Confucius, who was the first human to document the Cymbidium species in writing.
Cymbidium goeringii is a species of orchid that belongs to the family Orchidaceae. It is native to East Asia, including China, Japan, and Korea, and grows in cool, high-altitude regions. These plants are 'seasonal' growers, meaning they take cool temperatures, lower light, and drier conditions in the winter. The American Orchid Society notes that one terrestrial species, Cymbidium goeringii, grows at the most northern end of the genus' range.
Cymbidium goeringii, belonging to the Orchidaceae family, is an important ornamental plant with striking petals and lips. It has high economic value and characteristics include fragrance and multiple flower colours. The plant produces pseudobulbs, narrow strap-like leaves, and flowers typically in late winter to early spring. For medicinal and supplement purposes, various plant parts have been investigated, including the whole plant, roots, pseudobulbs, leaves, and flowers.
In both traditional and modern contexts, Cymbidium goeringii is prepared and used in several forms:
The cultivation and veneration of Cymbidium goeringii in East Asia predates recorded medicine. Literature references to orchid cultivation in China date back to before the time of Confucius (551–479 BC), and it is clear that Cymbidium species were among the earliest cultivated orchids. China has a long-standing tradition of Cymbidium cultivation and appreciation, which is credited to have begun as early as the Tang Dynasty, or possibly as far back as the Confucius period. Confucius (551–479 BC), for example, once said, "Che lan that grows in deep forests never withholds its fragrance even when it is not being appreciated" and that "lan is the king of fragrant plants." Lan has a special appeal and meaning to the Chinese as it symbolises integrity, modesty, and nobility. Confucius was full of praise for Lan as the "Gentleman of Noble Virtue" (君子之风) and "King of Fragrance" (王者之香).
Cymbidium goeringii has a longstanding history of use in East Asian traditional medicine, particularly in China, Korea, and Japan. Ancient texts often refer to Cymbidium goeringii as a tonic herb, valued for its ability to promote overall vitality and well-being.
In Chinese herbal medicine, Cymbidium goeringii is often included in formulations aimed at nourishing the lungs and treating conditions such as coughs, fatigue, and general debility. It was commonly administered to soothe coughs, alleviate symptoms of colds, and reduce phlegm. The herb was also believed to support healthy lung function and was used to restore voice hoarseness and treat mild respiratory infections.
Classical TCM texts, such as the "Bencao Gangmu" (Compendium of Materia Medica), document its use for symptoms including swelling, abscesses, and skin ulcers. The plant is sometimes applied topically or prepared as part of herbal formulas intended to "clear heat" and "remove toxins," concepts central to TCM approaches to wound healing.
Descriptions in historical texts and materia medica attribute to Cymbidium goeringii properties such as clearing heat, detoxifying, and resolving toxins, which in traditional Chinese medical theory may be linked to the treatment or prevention of infectious diseases.
Historical texts and traditional pharmacopeias reference its use for calming the spirit, reducing anxiety, and treating insomnia or related nervous conditions. In Traditional Chinese Medicine, it is sometimes included in formulations intended to "nourish the heart" and "calm the nerves" (anxiolytic and sedative purposes), though it is not among the most commonly used herbs for this function.
Historical texts, such as the "Bencao Gangmu" (Compendium of Materia Medica), mention Cymbidium species for their purported benefits in relieving pain, reducing inflammation, and promoting tissue healing. The use of Cymbidium goeringii as a general pain remedy is rooted in these traditional practices, where it may be included in decoctions or preparations to address pain associated with wounds, swelling, or musculoskeletal complaints.
In traditional herbal formulas, Cymbidium goeringii is rarely used alone. Instead, it is often combined with other botanicals to enhance synergistic effects. For example, it may be included with Rehmannia, Angelica, or Licorice root to bolster immune function, nourish the body, and improve energy levels.
The Cymbidium genus is a significant source of medicinal plants, containing a diverse range of bioactive compounds from various phytochemical classes. Spectroscopic analyses carried out by several researchers have highlighted the presence of phytochemicals in Cymbidium orchids. Although only a few reports are available, a notable richness in important bioactive compounds has been found in the genus. The majority of orchid taxa are known to have therapeutic potential due to the presence of bioactive substances, such as alkaloids, bibenzyls, phenanthrenes, phenanthrenequinones, glycosides, carbohydrates, flavonoids, and stilbenoids.
Phytochemical analyses have identified a range of bioactive compounds in Cymbidium goeringii, including alkaloids, polysaccharides, and phenolic compounds, some of which exhibit antioxidant and anti-inflammatory properties in laboratory studies.
The most extensively studied bioactive compound isolated specifically from C. goeringii is gigantol, a bibenzyl-type stilbenoid. During efforts to find bioactive natural products with anti-inflammatory activity, gigantol was isolated from the whole plants of Cymbidium goeringii (Orchidaceae) by activity-guided chromatographic fractionation. Gigantol belongs to the stilbenoid class of phenolic secondary metabolites that are widely distributed among orchid species. The different bioactive compounds found in Cymbidium species belong to chemical families such as monomeric stilbenes, bibenzyl, phenanthrene, flavonols, and dihydrophenanthrene, which have anti-bacterial, anti-nociceptive, anti-oxidant, anti-inflammatory, analgesic, and haemostatic effects.
A structurally unique compound, cymbidine A, has been isolated specifically from C. goeringii. The structure of a new monomeric peptidoglycan-related compound with hypotensive and diuretic activities, cymbidine A, isolated from the orchid Cymbidium goeringii, was elucidated mainly by spectroscopic analysis. The structure was shown to involve four amino acids (D-alanine, meso-diaminopimelic acid, D-glutamic acid, and L-valine) and two amino sugars (N-acetylglucosamine and 1,6-anhydro-N-acetylmuramic acid). The sequence of the amino acids and amino sugars was determined by the analysis of 2D NMR data. Notably, the absolute stereochemistries of the three amino acids (D-Ala, D-Glu, and L-Val) were determined by the modified Marfey's method. Cymbidine A is unusual in being a peptidoglycan-related compound found in a higher plant — a structural motif more commonly associated with bacterial cell walls.
Studies on Cymbidium sp. cultivation by-products (which include material from the broader Cymbidium genus) have documented a diverse range of phenanthrene-type compounds. Chromatographic separation of pseudobulb and root ethyl acetate extracts led to the isolation of 16 secondary metabolites — including four phenanthrenes, three 1,4-phenanthrenquinones, three dibenzyls, two phenolic acid derivatives, two sterols, one dehydrodiconiferyl alcohol derivative, and one simple phenolic compound — including 6-hydroxy-5,7-dimethoxy-1,4-phenanthrenequinone (cymbisamoquinone), which was identified as a new natural product.
Biological evaluation of isolated compounds from Cymbidium sp. revealed that gigantol and tristin present important anti-tyrosinase activity, while bulbophyllanthrin, 3-hydroxy-2,4,7-trimethoxy-phenanthrene, marylaurencinol A, 5-hydroxy-2-methoxy-1,4-phenanthrenequinone, and ephemeranthroquinone B show dose-dependent anti-collagenase activity.
Research documented by ResearchGate includes an investigation entitled "Isolation of Sterols from the Methanol Extracts of Cymbidium goeringii Reichb. fil.," confirming the presence of steroidal constituents in methanolic extracts of the plant. Sterols are widely distributed plant secondary metabolites and may contribute to the plant's overall biological activity profile.
RNA-sequencing studies have characterised the biosynthetic pathways responsible for the characteristic floral fragrance of C. goeringii. Keywords identified from transcriptomic analysis include sesquiterpenes, and RNA-seq and DEG data provided comprehensive gene expression information at the transcriptional level that could facilitate understanding of the molecular mechanisms of floral biosynthesis pathways in Cymbidium goeringii. These volatile components are of relevance to the use of the plant in fragrance and aromatherapy applications, though clinical evidence in these areas is absent.
The best-characterised mechanism of action for any constituent of C. goeringii is the inhibition of NF-κB signalling by gigantol. Gigantol was found to have potent inhibitory effects on LPS-induced nitric oxide (NO) and prostaglandin E₂ (PGE₂) production in RAW 264.7 cells. Consistent with these findings, gigantol suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at the protein and mRNA levels in RAW 264.7 cells in a concentration-dependent manner. The data also indicate that gigantol is a potent inhibitor of tumour necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) release, and influenced the mRNA expression levels of these cytokines in a dose-dependent manner. A reporter gene assay for NF-κB and an electromobility shift assay (EMSA) demonstrated that gigantol effectively inhibited the activation of NF-κB, which is necessary for the expression of iNOS, COX-2, TNF-α, IL-1β, and IL-6. Thus, studies suggest that gigantol inhibits LPS-induced iNOS and COX-2 expression by blocking NF-κB activation.
C. goeringii has shown hypotensive and diuretic activities when tested on mouse models (Watanabe et al., 2007). The compound responsible for these effects was identified as cymbidine A. Because cymbidine A shares structural features with bacterial peptidoglycan fragments, it may interact with pattern-recognition receptors (such as NOD receptors), though the precise mechanism at the molecular level in mammalian physiology has not been fully elucidated in published literature. This activity was demonstrated in preclinical (animal) models only.
Initial antioxidant, anti-tyrosinase, anti-elastase, and anti-collagenase assays of the total extracts of Cymbidium sp. pseudobulb and root material indicated that ethyl acetate extracts were the most potent. The biological evaluation of the isolated compounds revealed that gigantol and tristin present important anti-tyrosinase activity. In contrast to isolated metabolites, which may act selectively on specific enzymes, the initial total extracts exhibited inhibitory activity against tyrosinase, elastase, and collagenase enzymes, thus showing better prospects for use in dermo-cosmetic formulations.
Evidence level: Preclinical (in vitro); no human clinical data available.
The most rigorous published study on a constituent of C. goeringii and inflammation was conducted by Won et al. (2006), published in Planta Medica (PMID: 16924582). Gigantol was isolated from the whole plants of Cymbidium goeringii by activity-guided chromatographic fractionation and was found to have potent inhibitory effects on LPS-induced NO and PGE₂ production in RAW 264.7 cells. Gigantol was found to have potent inhibitory effects on LPS-induced nitric oxide and prostaglandin E₂ production in RAW 264.7 cells. It suppressed the expression of iNOS and COX-2 at the protein and mRNA levels in a concentration-dependent manner. It was also a potent inhibitor of TNF-α, IL-1β, and IL-6 release and influenced the mRNA expression levels of these cytokines in a dose-dependent manner. A reporter gene assay and EMSA demonstrated that gigantol effectively inhibited the activation of NF-κB. This study was performed entirely in cultured murine macrophage cells (RAW 264.7) and therefore constitutes in vitro evidence only. No animal models or human clinical trials on anti-inflammatory outcomes for C. goeringii or its constituents have been identified in the peer-reviewed literature.
Evidence level: Preclinical (in vitro); no human clinical data available.
In vitro research has demonstrated that extracts from the plant may help attenuate oxidative stress and modulate immune responses, suggesting potential benefits for overall health and disease prevention. Studies on Cymbidium sp. extracts (relevant to the broader genus) showed that antioxidant assays of the total extracts indicated that the pseudobulb and root ethyl acetate extracts were the most potent. Gigantol has been separately noted in the scientific literature for displaying antioxidant activity when studied in other Orchidaceae species contexts. No clinical antioxidant outcome data for C. goeringii specifically have been published.
Evidence level: Preclinical (animal model only); no human clinical data available.
Watanabe et al. (2007) reported the structure of cymbidine A, a monomeric peptidoglycan-related compound with hypotensive and diuretic activities, isolated from a higher plant, Cymbidium goeringii (Orchidaceae), published in the Chemical and Pharmaceutical Bulletin, 55(5): 780–783. The hypotensive and diuretic activities were documented in animal models. No human trials have investigated cardiovascular or diuretic effects of C. goeringii or cymbidine A.
Evidence level: Preliminary; limited to genus-level or in vitro data.
A variety of biological activities, including anti-microbial, anti-cancerous, anti-inflammatory, spasmolytic, and analgesic, have been reported from the extracts of Cymbidium orchids. However, modern scientific studies specifically investigating the antiviral effects of Cymbidium goeringii are limited, and there is a lack of robust clinical evidence demonstrating efficacy against viral infections. Some in vitro studies have investigated related Cymbidium species for general antimicrobial or anti-inflammatory activities, but these do not constitute strong evidence for the species specifically. No peer-reviewed clinical or animal studies specifically on the antimicrobial activity of C. goeringii were identified.
Evidence level: In vitro only; no clinical trials available.
A 2022 study published in Antioxidants (PMC8772768) investigated the phytochemical composition and dermo-cosmetic potential of Cymbidium sp. cultivation by-products. The by-products were studied through phytochemical analysis and investigated for their dermo-cosmetic potential; initial antioxidant, anti-tyrosinase, anti-elastase, and anti-collagenase assays of the total extracts indicated that the pseudobulb and root ethyl acetate extracts were the most potent. Gigantol and tristin presented important anti-tyrosinase activity, and several phenanthrene-derived compounds showed dose-dependent anti-collagenase activity. These results are exclusively in vitro enzyme inhibition assays, not clinical studies. Implications for skin whitening (tyrosinase inhibition) or anti-ageing (collagenase/elastase inhibition) in humans remain speculative at this stage.
Evidence level: Traditional use only; no modern scientific validation.
There is little modern scientific research directly supporting or explaining the efficacy of Cymbidium goeringii for wound healing. While some studies have examined related Cymbidium species for antioxidant or anti-inflammatory activities, peer-reviewed studies specifically on C. goeringii for wound treatment are sparse. The continued use in folk and traditional settings is thus primarily justified by historical practice rather than scientific validation.
Evidence level: Traditional use only; no modern scientific validation.
Modern scientific research on Cymbidium goeringii with respect to its effects on the nervous system is very limited. There are a few phytochemical studies indicating the presence of glycosides, alkaloids, and other potentially bioactive compounds, but direct evidence from clinical or animal studies supporting its efficacy for neurological or nervous system conditions is lacking.
Evidence level: Traditional use only; evidence is weak and unsubstantiated by modern studies.
Modern scientific research on the analgesic properties of Cymbidium goeringii is extremely limited. While some in vitro and animal studies have explored related Cymbidium species for antioxidant or anti-inflammatory effects, there is a lack of robust clinical evidence or pharmacological studies directly linking C. goeringii to effective pain relief. The use for pain is primarily justified by tradition, with minimal scientific validation.
Human clinical trials assessing the nutritional or therapeutic efficacy of Cymbidium goeringii remain limited. While preliminary animal studies and cell-based experiments provide encouraging data, definitive evidence regarding its health benefits in humans is still lacking. There is vast potential for discovering new bioactive compounds in the genus Cymbidium for drug discovery, but scientific validation for its herbal usage is confined to only some species.
No human clinical trials have been published that establish an evidence-based dosage regimen for Cymbidium goeringii extract or any of its isolated constituents. The following information reflects only what has been documented in available sources:
No peer-reviewed toxicological studies, human safety trials, or formal risk assessments specifically for Cymbidium goeringii extract were identified in any authoritative database reviewed for this article. Human clinical trials assessing the efficacy of Cymbidium goeringii remain limited, and while preliminary animal studies and cell-based experiments provide encouraging data, definitive evidence regarding its health effects in humans is still lacking.
A significant safety concern documented by the Banned Substances Control Group (BSCG), an independent drug-testing organisation, relates to the marketed ingredient "Orchilean™." It is not clear what Orchilean is or whether it is present in Cymbidium goeringii extract as suggested. Orchilean may be similar to DEPEA. It was marketed as a replacement to DMAA. Cymbidium goeringii is a legitimate natural product used in essential oils. This means that commercial products labelled as containing Cymbidium goeringii extract or "Orchilean" may not contain what their labels claim, and may potentially contain undisclosed synthetic stimulants. DEPEA (N,N-diethylphenethylamine) and DMAA (1,3-dimethylamylamine) are synthetic stimulants that have been subject to regulatory scrutiny.
The NIH's Dietary Supplement Label Database (DSLD) is a searchable database of current and historical label information from products marketed in the U.S., and Cymbidium goeringii appears as a listed ingredient. This listing reflects market presence, not a safety endorsement or approved health claim.
No peer-reviewed studies have specifically investigated pharmacokinetic drug interactions, contraindications, or adverse event profiles for Cymbidium goeringii extract or its isolated constituents in humans. The identification of cymbidine A as a hypotensive and diuretic agent in animal models suggests theoretical caution regarding concomitant use with antihypertensive medications or diuretics, as additive effects cannot be excluded. However, no clinical interaction data exist to confirm or quantify this risk.
Orchids are one of the largest, diverse, and most evolved groups of plants within monocot angiosperms. Different species under this category have been recognised as the most threatened plants due to poor seed germination, the need for endophytic mycorrhizal partners, and habitat destruction coupled with climate change. As a species native to East Asia that has historically been over-collected for ornamental and medicinal use, the sustainability of wild-harvested C. goeringii material is a consideration in the supply chain for any commercial preparations.
Health conditions that Cymbidium goeringii may help support.
Body systems that Cymbidium goeringii may help support.
Go back